Sarepta TherapeuticsSRPT
Recorded

Sarepta Therapeutics 2026 Q3 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ3 2026Duration1 hr 11 minParticipants22

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Good afternoon and welcome to Sarepta's third quarter 2026 earnings results call. As a reminder, today's program is being recorded. At this time, I'll turn the call over to Tam Thornton, Senior Director of Investor Relations.

Tam ThorntonSenior Director of Investor Relations

Please go ahead. Thank you, Michelle, and thank you all for joining today's call.

Tam ThorntonSenior Director of Investor Relations

Earlier this afternoon, we released our financial results for the third quarter of 2026. The press release, along with our presentation slides and supplementary information, are available on the investor section of our company website. We plan to file our Form 10-Q for the quarter today with the SEC. Joining me on the call today are Mike Severino, our Chief Executive Officer, Dr. Louise Rodino-Klapac, President of Research and Development and Technical Operations, Patrick Moss, our Chief Commercial Officer, and Ryan Wong, our Chief Financial Officer. Additionally, joining us in the Q&A portion of the call are Ian Estepan, President and Chief Operations Officer, and Dr. James Richardson, our Chief Medical Officer. Before we begin the formal remarks, I would like to note that during this call, we will be making a number of forward-looking statements.

Tam ThorntonSenior Director of Investor Relations

Please refer to slide two of our presentation to view the formal text of these safe harbor statements. These statements involve varying risks and uncertainties, many of which are beyond Sarepta's control. Actual results could materially differ from these forward-looking statements, and such risks can adversely affect our business, our results of operations, and the trading price for Sarepta's common stock. We strongly encourage all listeners to review the company's most recent SEC filings for a detailed description of these applicable risks. Sarepta explicitly states that it does not undertake any obligation to publicly update or revise its forward-looking statements or financial projections based on subsequent events. Furthermore, please note that we will discuss non-GAAP financial measures during today's webcast. Complete descriptions and reconciliations of our GAAP to non-GAAP financial measures are included in today's press release and the accompanying slide presentation available to investors on our website.

Tam ThorntonSenior Director of Investor Relations

With that, I will now turn the call over to our CEO, Mike Severino.

Michael SeverinoCEO

Thanks, Tam. Good afternoon, everyone, and thank you for joining us. It has been a little over 90 days since I joined Sarepta, and I want to begin by sharing a few reflections from that time and how they are shaping my priorities for the company. What initially attracted me to Sarepta was a combination that I believe is unique in biotech at our scale: an established commercial business and leadership position in Duchenne, a promising pipeline with the potential to produce differentiated medicines, and the financial strength to invest in that pipeline from our own commercial cash flows. After my first 90 days, I believe those fundamental strengths are very much intact.

Michael SeverinoCEO

At the same time, I joined the company following a challenging period, so I have been deliberate in focusing on evaluating the business objectively and identifying clear competitive advantages, opportunities where we can improve execution, and areas where investment has the potential to generate the greatest long-term value. My observations are informed by interactions with our stakeholders, physicians, patients, investors, and employees. As Sarepta employees have welcomed me into the organization, I have been impressed with their talent, resilience, deep dedication to serving patients, and shared commitment to advancing the opportunities in front of us. Turning first to our commercial business, our immediate priority has been to reinforce the strength of the broader Duchenne franchise while stabilizing ELEVIDYS demand. During the quarter, enrollment form activity for ELEVIDYS was in line with the second quarter.

Michael SeverinoCEO

We believe that this establishes a new baseline that we can use to assess the effectiveness of our commercial initiatives going forward. We are also bringing a growing body of clinical evidence, including new long-term data and data in the important 8 to 12-year age range, into our conversations with physicians and families, enabling us to put the benefit-risk profile of ELEVIDYS into the appropriate context. Importantly, this quarter also demonstrated the continued strength of our PMO franchise. Based on our strong PMO performance and stabilization in ELEVIDYS, we are raising the low end of our 2026 total net product revenue guidance and narrowing the range to $1.25 billion-$1.3 billion. Patrick will discuss our commercial performance and outlook in greater detail shortly. Second, I will turn my attention to the promise of our pipeline.

Michael SeverinoCEO

One of my strongest conclusions from my first 90 days is that the potential of our pipeline, particularly in DM1 and FSHD, is not yet fully reflected in how Sarepta is viewed today. These are genetically defined diseases where the underlying biology is well understood. We have shown robust knockdown of disease-causing mutations in a number of preclinical systems, and promising data from our SAD studies supports their potential to be differentiated therapies. The next step is to demonstrate that these observations extend to a multiple-dose setting and demonstrate consistent, robust knockdown, leading to the downstream biologic effects we believe will predict long-term clinical benefit. Our multiple ascending dose datasets, which we expect to share in the upcoming weeks, are designed to provide the data necessary to move both programs into late-stage development.

Michael SeverinoCEO

In anticipation of these data, we are already preparing for the initiation of registrational studies for both programs. While we are preparing to move forward with a sense of urgency, we will preserve the ability to learn from the emerging competitive landscape and our discussions with regulators to inform the optimal development and regulatory path. Louise will provide more detail on these programs, as well as our progress across the Duchenne clinical portfolio, in her section. Third, I would like to highlight our financial strength, which I view as an important strategic pillar for Sarepta. Revenues from our commercial portfolio provide us with the ability to fund the high-value opportunities in our pipeline while retaining flexibility around how and when we deploy capital.

Michael SeverinoCEO

We intend to remain rigorous about where we invest, prioritizing programs where we believe Sarepta has a scientific or commercial advantage, and maintaining discipline across the broader cost structure. Ryan will provide more detail on the quarter, but our continued non-GAAP profitability, cash generation, and balance sheet strength give us the flexibility to invest through the important catalysts ahead while maintaining a disciplined approach to capital allocation. As I look ahead, my view after 90 days is one of focused optimism. We have work to do, and I want us to be measured by execution, but we also have assets that I believe position Sarepta well for its next chapter: a durable Duchenne franchise, potentially differentiated opportunities in DM1 and FSHD, deep capabilities in rare and neuromuscular disease, and the financial strength to advance those opportunities.

Michael SeverinoCEO

Over the coming quarters, I believe the markers of our progress will become increasingly tangible: continued execution in ELEVIDYS, potentially differentiated clinical data from our siRNA programs, disciplined advancement of our highest-value pipeline opportunities, and consistent financial execution. If we deliver against these priorities, I believe we can strengthen the foundation of the business while positioning Sarepta for meaningful long-term value creation. With that, let me turn the call over to Patrick to discuss our commercial performance.

Patrick MossChief Commercial Officer

Patrick? Thank you, Mike. Today, I will review our third quarter commercial performance, the work we are doing to support treatment decisions for ELEVIDYS, and the continued strength of our broader Duchenne business.

Patrick MossChief Commercial Officer

Our third quarter resulted in total net product revenue of approximately $324 million, including $83 million of net revenue from ELEVIDYS and $240 million from our PMO franchise. For ELEVIDYS, we are seeing stabilization in the business, and our exon-skipping franchise continues to demonstrate strong and durable performance. The commercial organization is executing well. We continue to hear positive feedback that our field team's efforts are being well received, with physicians and centers appreciating the support, education, and coordination. Key leading indicators for ELEVIDYS and enrollment forms in the third quarter were in line with Q2 and above where we started the year. Willingness to treat remains solid, and recent start form activity supports our current run rate.

Patrick MossChief Commercial Officer

We continue to remain focused on execution, identifying patients, and helping physicians and families understand the long-term evidence for ELEVIDYS, including the recently published three-year EMBARK results. Our sales team brought these data to healthcare providers across our sites of care and referral networks this quarter. What we hear in our engagement with HCPs is that the three-year EMBARK data resonates. With more than 1,500 patients now treated, ELEVIDYS has a depth of real-world evidence that is unique in Duchenne. We believe these data are helping physicians and families better appreciate the long-term benefits of ELEVIDYS. For physicians, the data reinforces what they observed in their own patients treated with ELEVIDYS, and some who have had a period of inactivity are returning to prescribe. We believe this evidence is having an impact as HCPs bring it into conversations with Duchenne families.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day